{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-033922","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.452020+00:00","generated_at":"2026-05-30T04:13:33.289499+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback","bullets":["Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.","Completed sale of select BioReference Health assets to Labcorp for $237.5M; continues oncology/urology nationwide.","Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share payments from Pfizer.","Board authorized $100M share repurchase program; repurchased 14.9M shares for $23.8M in Q3 and 8.7M more through Nov 6.","Awarded $51M additional BARDA funding ($26.9M COVID, $24.1M influenza) for ModeX multispecific antibodies."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-033922","json":"https://secwatch.observer/filing/0001437749-24-033922.json","markdown":"https://secwatch.observer/filing/0001437749-24-033922.md","text":"https://secwatch.observer/filing/0001437749-24-033922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774924033922/0001437749-24-033922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774924033922/opk20241029_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:13:33.289499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}